Get the Stockscreener App
153.45
1.77%
2.37
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $153.45, with a volume of 144.24K.
It is up +1.77% in the last 24 hours and up +10.54% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$151.08
Open:
$150.89
24h Volume:
144.24K
Relative Volume:
0.73
Market Cap:
$3.01B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
61.14
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
+4.59%
1M Performance:
+10.54%
6M Performance:
+28.14%
1Y Performance:
+50.44%
1-Day Range:
$149.51
$154.89
1-Week Range:
$149.00
$157.54
52-Week Range:
$93.58
$157.54
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
153.76 | 2.98B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.52 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.32 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.19 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.40 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.20 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Published on: 2025-08-18 01:20:46 - sundaytimes.kr
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionJuly 2025 News Drivers & Daily Growth Stock Tips - beatles.ru
What to do if you’re stuck in Ligand Pharmaceuticals IncorporatedDividend Hike & AI Forecast for Swing Trade Picks - Newser
Ligand Pharmaceuticals Incorporated Shows Early Signs of Technical Strength2025 Trading Recap & Free High Accuracy Swing Entry Alerts - sundaytimes.kr
Ligand Pharmaceuticals raises $400mln through convertible senior notes offering. - AInvest
Ligand Pharma Completes $460M Convertible Notes Offering - TipRanks
Ligand Pharmaceuticals completes $460 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Announces Closing of Convertible Senior Notes Offering - Yahoo Finance
Detecting support and resistance levels for Ligand Pharmaceuticals IncorporatedWeekly Market Summary & Expert Approved Momentum Ideas - Newser
US Bancorp DE Purchases 3,301 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $185.00 - MarketBeat
Ligand Pharmaceuticals shares rise 3.65% intraday after pricing $400 million convertible senior notes offering. - AInvest
Ligand's $400M Convertible Notes Offering: A Strategic Move for M&A-Driven Growth and Shareholder Value - AInvest
Ligand Pharmaceuticals Stock (LGND) Opinions on $400M Convertible Notes Offering - Quiver Quantitative
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Yahoo Finance
Ligand Prices $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharmaceuticals Prices Offering Of $400 Mln Of Senior Notes - Nasdaq
Ligand Pharmaceuticals Experiences Strong Q2 Earnings with Robust Revenue Growth, Successful Mergers and Investments, and Raised Financial Guidance. - AInvest
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Ligand Pharmaceuticals Secures $400M in Convertible Debt Offering - AInvest
Ligand Pharmaceuticals' Convertible Notes Offering: A Strategic Move for Capital Optimization and Growth - AInvest
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering | LGND Stock News - GuruFocus
Ligand Pharmaceuticals prices $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand's Convertible Notes Offering: Balancing Dilution Risks and Strategic Flexibility in Biopharma Financing - AInvest
Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 - Quiver Quantitative
Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback - Stock Titan
Ligand prices $400 million convertible senior notes offering - MarketScreener
Ligand Pharmaceuticals Prices $400M Convertible Senior Notes Offering - AInvest
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
LGNDLigand Pharma Latest Stock News & Market Updates - Stock Titan
Ligand Pharmaceuticals Inc. Reports Strong Q2 Earnings - TipRanks
LGND: Getting In Tune with MedTech - Zacks Small Cap Research
Ligand Pharmaceuticals to offer $400M convertible senior notes in private placement - MSN
Ligand Pharmaceuticals Plans $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes - Nasdaq
Ligand Pharmaceuticals shares fall 4.06% premarket after announcing a $400 million convertible senior notes offering. - AInvest
Ligand Announces $400M Convertible Senior Notes Offering Due 2030. - AInvest
Ligand Pharmaceuticals plans $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Offer $400mln Convertible Senior Notes Due 2030. - AInvest
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - MarketScreener
Analyzing Ligand Pharmaceuticals Incorporated with risk reward ratio chartsMonthly Long-Term Market Recap and Summary - Newser
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest
Will Ligand Pharmaceuticals Incorporated Recover After Recent DeclineStable Entry High Return Opportunities in Focus - beatles.ru
Royal Bank Of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - Defense World
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $157 to $185 - 富途牛牛
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2025 Earnings Call Transcript - Insider Monkey
Published on: 2025-08-09 07:41:08 - beatles.ru
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Upgraded by Wall Street Zen - Defense World
Ligand Pharmaceuticals shares rise 3.05% intraday after Q2 2025 earnings call. - AInvest
Ligand: RBC Raises PT to $185, Maintains Outperform Rating - AInvest
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):